CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN), a leading provider of essential life sciences technologies for research, production and diagnostics, announced today it has entered into an exclusive agreement with Brendan Technologies (OTCBB:BDTE) to customize its StatLIA® assay analysis software to facilitate the analysis of protein samples. Financial terms of the agreement were not disclosed.